- Home
- SES vs OCGN Comparison
SES vs OCGN Comparison
Compare SES & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SES
- OCGN
- Stock Information
- Founded
- SES 2012
- OCGN 2013
- Country
- SES United States
- OCGN United States
- Employees
- SES N/A
- OCGN N/A
- Industry
- SES Auto Parts:O.E.M.
- OCGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SES Consumer Discretionary
- OCGN Health Care
- Exchange
- SES Nasdaq
- OCGN Nasdaq
- Market Cap
- SES 355.0M
- OCGN 338.2M
- IPO Year
- SES N/A
- OCGN N/A
- Fundamental
- Price
- SES $0.62
- OCGN $1.01
- Analyst Decision
- SES Sell
- OCGN Strong Buy
- Analyst Count
- SES 2
- OCGN 2
- Target Price
- SES $1.25
- OCGN $6.00
- AVG Volume (30 Days)
- SES 5.2M
- OCGN 3.8M
- Earning Date
- SES 11-05-2024
- OCGN 11-07-2024
- Dividend Yield
- SES N/A
- OCGN N/A
- EPS Growth
- SES N/A
- OCGN N/A
- EPS
- SES N/A
- OCGN N/A
- Revenue
- SES N/A
- OCGN $7,263,000.00
- Revenue This Year
- SES N/A
- OCGN N/A
- Revenue Next Year
- SES N/A
- OCGN N/A
- P/E Ratio
- SES N/A
- OCGN N/A
- Revenue Growth
- SES N/A
- OCGN 112.62
- 52 Week Low
- SES $0.57
- OCGN $0.35
- 52 Week High
- SES $2.66
- OCGN $2.11
- Technical
- Relative Strength Index (RSI)
- SES 31.32
- OCGN 41.06
- Support Level
- SES $0.57
- OCGN $0.92
- Resistance Level
- SES $0.79
- OCGN $1.05
- Average True Range (ATR)
- SES 0.11
- OCGN 0.07
- MACD
- SES -0.02
- OCGN -0.00
- Stochastic Oscillator
- SES 7.90
- OCGN 31.34
About SES SES AI Corporation
SES AI Corp is a pre-commercialization stage company engaged in the development and initial production of high-performance Lithium-Metal (Li-Metal) rechargeable battery technologies for electric vehicles (EVs), urban air mobility (UAM), which encompasses electric vehicle take-off and landing (eVTOL), and other applications. The company is an integrated Li-Metal battery manufacturer with capabilities in material, cell, module, AI-powered safety algorithms, and recycling.
About OCGN Ocugen Inc.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").